The FDA approval of the Pushtronex once-a-month dosing system for evolocumab is a nice addition to our treatment regimen for patients with statin-refractory hypercholesterolemia.

Amgen announced that the Food and Drug Administration (FDA) has approved Repatha (evolocumab) Pushtronex system, an on-body infusor with a prefilled cartridge intended for once-monthly administration.

THOUSAND OAKS, Calif., Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha ® (evolocumab) Pushtronex ™ system (on-body infusor with prefilled cartridge), a ...

Also available is the Repatha Pushtronex system, ... Dufour R, et al; RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia ...

Amgen said the FDA has approved its Repatha (evolocumab) Pushtronex system, the first hands-free, once-monthly delivery option for a PCSK9 inhibitor. Evolocumab is indicated as an adjunct to diet ...

Amgen announced that as part of the company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and ...

“Evolocumab therapy could meet the threshold of $150 000 per QALY with an annual value-based price of $9669 for a population with an event rate of 6.4 per 100 patient-years,” the authors ...

The absolute change in the LDL cholesterol level was −77.5 mg/dL in the evolocumab group and −9.0 mg/dL in the placebo group, giving a difference of −68.6 mg/dL (P < .001).

Evolocumab injections conferred a significantly reduced risk for the primary endpoint among patients with autoimmune or inflammatory disease compared with placebo (HR = 0.58; 95% CI, 0.38-0.89; P ...

Amgen AMGN revealed that the Food and Drug Administration (FDA) has approved the Repatha (evolocumab) Pushtronex system, a fresh, monthly single-dose administration option. According to the ...

At 48 weeks in the evolocumab group, the LDL cholesterol level was reduced to 70 mg per deciliter (1.8 mmol per liter) or lower in 87% of the patients, to 40 mg per deciliter (1.0 mmol per liter ...

The FINANCIAL -- Amgen on July 11 announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha (evolocumab) Pushtronex system (on-body infusor with prefilled cartridge), a ...